With an estimated21%ofhorsesovertheageof 15affectedbypituitary pars intermedia dysfunction(PPID),1ongoing monitoring playsacriticalroleinmanagingthis progressive condition. To further support veterinarians in evaluating treatment response, Boehringer Ingelheim has added a recheck component to its IDPPID testing program.Starting with the current spring 2026 testing period, eligible horses newly diagnosed with PPID and undergoingtreatment withPrascend (pergolide tablets)maybereevaluatedthroughtheprogram.This update enables veterinarians to assess changes in endocrine health alongside clinical signs, helping inform next steps in disease management. Veterinarians can contact their Boehringer territory manager withquestions or for more information.PPID is a progressive disease, says SteveGrubbs, DVM, PhD, Dipl. ACVIM, technical manager,Equine, BoehringerIngelheim. By offeringa recheck,we are providingveterinarianswith additionalvaluable information to help guide treatment protocols, while continuing to build ourunderstanding ofPPIDandits progression.SincetheIDPPIDprogramsinceptionin2013, morethan65,000horseshavebeentested,2resulting in horses being diagnosed and subsequently treated for PPID.Besides rechecking horseswithPPID via adrenocorticotropic hormone (ACTH), insulin, and glucosetesting, Grubbs recommends continuing to monitor changes in clinical signs observed at initial diagnosis.Thesesignscanincludechanges inattitude, decreasedperformance,delayedhaircoatshedding, and loss of topline muscle in the early stages. If the condition is more advanced, recurrent infections, exercise intolerance, and generalized muscle atrophy might be present.ThespringtestingperiodiscurrentlyopenthroughJune9,2026.ThefalltestingperiodrunsAug.18Oct.13.Formoredetails,visitIDPPID.com.1GrubbsST,NealDLandKeefeTJ.EpidemiologicalcharacteristicsofhorseswithPPIDatinitialdiagnosis.Boehringer Ingelheim Animal Health USA Inc., St. Joseph, Mo., and Colorado StateUniversity,FortCollins,Co.2020.2IDPPIDTestingProgram,2013-2025.Dataonfile.